The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar in the U.S. from Formycon and Bioeq, the companies announced in a press release.
Additionally, Zydus Lifesciences Global FZE has entered a strategic partnership with Bioeq. Under the terms of the agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the biosimilar, while Zydus will control its commercialization in the U.S. market.
Nufymco (ranibizumab-leyk), a VEGF inhibitor, is indicated for the treatment of retinal diseases